Been pretty obvious that ARDS was a 1 in a million chance. Pretty obvious since middle of the year, everyone knew that SOC was improving, everyone knew we needed luck that the placebo cohort would die.
Can't really blame FDA, should just blame yourself for thinking that a 12 patients trial that yielded 83% survival would continue in a phase 3 trial. And to be very clear unless you were thinking rem-l was only designed or suitable for younger patients then why didn't MSB make that clear before the trial started? Because they believed it was applicable for everyone. Investors can't blame anyone for not doing their own research on ARDS themselves. Pretty obvious result on this one.
Move on and focus on MSB key products, CHF, CLBP. Not on ARDS novelty which to me is distraction.
MSB Trading 2020 - a new dawn, page-12681
-
- There are more pages in this discussion • 390 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 94863 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 5000 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |